Fairvalue-Calculator Fairvalue-Calculator
EN DE

Tdspharm Co (464280) Fair Value & Analysis

Healthcare · KR · Market cap 34.4B KRW

Price5,910 KRW
Fair Value12,521 KRW
Upside+111.9%
Quality95/100
Evidence: Medium Range 8,764 KRW – 16,277 KRW

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Tdspharm Co (464280) currently trades at 5,910 KRW, while our model-based Fair Value estimate is 12,521 KRW — implying the stock looks roughly 111.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Tdspharm Co., Ltd. researches, develops, and produces pharmaceuticals and cosmetics in South Korea and internationally. It offers general medicines, prescription drugs, and non-medicinal products. The company was founded in 2002 and is based in Seongnam-si, South Korea.

Open the full interactive analysis →

Similar stocks

Eli Lilly and Company (LLY) -64% Johnson & Johnson, (JNJ) -96% AbbVie Inc (ABBV) -71% Roche Holding (ROGN) -96% Merck & Co (MRCK34) -81% AstraZeneca PLC (A1ZN34) -84%

Frequently asked questions

Is Tdspharm Co (464280) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 12,521 KRW versus a price of 5,910 KRW — about +112% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 464280?
Our 21-model fair value for Tdspharm Co is 12,521 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 5,910 KRW.
What is the quality score of 464280?
Tdspharm Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.